Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-72745-6
Affiliations:
7
Authors:
12
Go to article
Institutions Authors Share
Fudan University Shanghai Cancer Center (FUSCC), China
10.000000
10.000000
 0.83
Shanghai Chest Hospital, SJTU, China
1.000000
 0.08
Canhelp Genomics, China
1.000000
 0.08
Interested in Oncology and Carcinogenesis?